{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:01:49Z","timestamp":1790233309051,"version":"4.1.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Human leukocyte antigen-G (HLA-G) is a non-classical major histocompatibility complex class I molecule that functions as an immune checkpoint via inhibitory receptors such as immunoglobulin-like transcript 2 (ILT2), immunoglobulin-like transcript 4 (ILT4) and killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4), suppressing anti-tumor immunity. Its prevalence and regulation across solid tumors remain incompletely defined due to low expression, spatial heterogeneity, and detection challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a multimodal target prevalence analysis integrating data from a validated immunohistochemistry (IHC) assay for protein detection and prospective screening data from a phase 1 study of an HLA-G \u00d7 CD3 T cell bispecific antibody (Clintrials.gov identifier: NCT05769959) with bulk RNA sequencing from early-phase oncology clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Analysis of 252 patient tumor samples using an investigational HLA-G IHC assay showed that 59.9% were HLA-G positive, with highest prevalence in ovarian cancer (89%), non-small cell lung cancer (NSCLC) (76%), renal cell carcinoma (RCC) (71%), and pancreatic cancer (70%). Expression was generally low to moderate and spatially heterogeneous. Notably, discordance between transcript and protein expression was observed in melanoma, where high mRNA levels were not matched by detectable protein, suggesting post-transcriptional regulation. Prospective screening in a phase 1 cohort confirmed a high target positivity rate (77.5%). At the transcript level, HLA-G expression was enriched in inflamed tumors and correlated with interferon gamma (IFN-\u03b3) signaling, antigen presentation pathways, and effector T-cell markers including cluster of differentiation 8 alpha (\n                      <jats:italic>CD8A<\/jats:italic>\n                      ), interferon gamma gene (\n                      <jats:italic>IFNG<\/jats:italic>\n                      ) and granzyme B (\n                      <jats:italic>GZMB<\/jats:italic>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HLA-G appears to be an inducible immune checkpoint associated with IFN-\u03b3-driven immune activation and adaptive resistance. Transcript-protein discordance and spatial heterogeneity highlight the need for protein-level assessment in biomarker development. These findings inform companion diagnostic strategies for HLA-G-directed immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1876556","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:30:35Z","timestamp":1790231435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal characterization of HLA-G expression across solid tumors reveals transcript-protein discordance and implications for immunotherapy targeting"],"prefix":"10.3389","volume":"17","author":[{"given":"Alexandra","family":"Epp","sequence":"first","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich","place":["Penzberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Serrano-Serrano","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Heil","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich","place":["Penzberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher","family":"Majety","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Discovery Oncology, Roche Innovation Center Munich","place":["Penzberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Silva","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich","place":["Penzberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Cheung","sequence":"additional","affiliation":[{"name":"Pharma Services Assay Development, Roche Tissue Diagnostics","place":["Oro Valley, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Colpan","sequence":"additional","affiliation":[{"name":"Pharma Services Assay Development, Roche Tissue Diagnostics","place":["Oro Valley, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Nair","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd.","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228678","article-title":"The molecular and functional characteristics of HLA-G and the interaction with its receptors: where to intervene for cancer immunotherapy","volume":"21","author":"Attia","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1761266","article-title":"The non-classical immune checkpoint HLA-G: a regulatory master switch governing tolerance, evasion, and translational frontiers","volume":"16","author":"Liu","year":"2026","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013313","article-title":"Unlocking the promise of innate biology through the HLA-G\/ILT2\/ILT4 pathway","volume":"14","author":"Beers","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B4","article-title":"HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer","volume":"7","author":"Zhou","year":"2015","journal-title":"Am J Transl Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165813","article-title":"Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis","volume":"14","author":"Bartolome","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G: an immune checkpoint molecule","volume":"127","author":"Carosella","year":"2015","journal-title":"Adv Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0198-8859(00)00207-x","article-title":"Reaction patterns of monoclonal antibodies to HLA-G in human tissues and on cell lines: a comparative study","volume":"61","author":"Blaschitz","year":"2000","journal-title":"Hum Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/298569","article-title":"Immunomodulatory properties of HLA-G in infectious diseases","volume":"2014","author":"Amiot","year":"2014","journal-title":"J Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124528","article-title":"HLA-G: a new immune checkpoint in cancer","volume":"21","author":"Krijgsman","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.698677","article-title":"HLA-G\/ILTs targeted solid cancer immunotherapy: opportunities and challenges","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.111876","article-title":"JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G","volume":"28","author":"Obermajer","year":"2025","journal-title":"iScience"},{"key":"B12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00262-024-03790-7","article-title":"Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) \u00d7 CD3 bispecific antibody, for the treatment of advanced stage solid tumors","volume":"73","author":"Geva","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.796054","article-title":"HLA-G: too much or too little? Role in cancer and autoimmune disease","volume":"13","author":"Mart\u00edn-Villa","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008185","article-title":"Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials","volume":"12","author":"Roller","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B15","article-title":"HTSeqGenie: a software package to analyse high-throughput sequencing experiments","author":"Pau","year":"2024","journal-title":"Bioconductor"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3252","article-title":"Orchestrating high-throughput genomic analysis with Bioconductor","volume":"12","author":"Huber","year":"2015","journal-title":"Nat Methods"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq057","article-title":"Fast and SNP-tolerant detection of complex variants and splicing in short reads","volume":"26","author":"Wu","year":"2010","journal-title":"Bioinformatics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12864-017-3661-2","article-title":"Detect tissue heterogeneity in gene expression data with BioQC","volume":"18","author":"Zhang","year":"2017","journal-title":"BMC Genomics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-010-0583-4","article-title":"Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention","volume":"68","author":"Amiot","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01685","article-title":"HLA-G neo-expression on tumors","volume":"11","author":"Loustau","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1876556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:30:37Z","timestamp":1790231437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1876556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":21,"alternative-id":["10.3389\/fimmu.2026.1876556"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1876556","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1876556"}}